Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ovarian cancer drug combo shows promise in slowing disease

NCT ID NCT01081951

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This study tested whether adding the drug olaparib to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced ovarian cancer live longer without their cancer getting worse. It included 162 adults whose cancer had previously responded to platinum-based treatment. The main goal was to see if the combination delayed cancer progression compared to chemotherapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

162 people

The number who actually took part.

Started

Feb 2010

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 125 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with serous ovarian cancer * Patients who have received no more than 3 previous platinum containing treatments and were progression free for at least 6 months following the end of the last platinum treatment * At least one lesion that is suitable for accurate repeated measurements Exclusion Criteria: * Patients receiving any systemic anticancer chemotherapy, radiotherapy (except palliative) within two weeks from the last dose prior to study treatment * Hypersensitivity to pre medications required for treatment with paclitaxel/carboplatin

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

Contacts and locations

Locations

  • Research Site

    Stanford, California, 94305, United States

  • Research Site

    West Hollywood, California, 90048, United States

  • Research Site

    Orlando, Florida, 32806, United States

  • Research Site

    Indianapolis, Indiana, 46202, United States

  • Research Site

    Boston, Massachusetts, 02114, United States

  • Research Site

    Boston, Massachusetts, 02215, United States

  • Research Site

    New York, New York, 10016, United States

  • Research Site

    Portland, Oregon, 97227-1191, United States

  • Research Site

    Parkville, 3050, Australia

  • Research Site

    Randwick, 2031, Australia

  • Research Site

    Brussels, 1090, Belgium

  • Research Site

    Leuven, 3000, Belgium

  • Research Site

    Namur, 5000, Belgium

  • Research Site

    Wilrijk, 2610, Belgium

  • Research Site

    Vancouver, British Columbia, V5Z 4E6, Canada

  • Research Site

    Hamilton, Ontario, L8V 5C2, Canada

  • Research Site

    Toronto, Ontario, M4N 3M5, Canada

  • Research Site

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    Québec, Quebec, G1R 2J6, Canada

  • Research Site

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Research Site

    Brno, 625 00, Czechia

  • Research Site

    Brno, 656 53, Czechia

  • Research Site

    Hradec Králové, 500 05, Czechia

  • Research Site

    Olomouc, 775 20, Czechia

  • Research Site

    Prague, 120 00, Czechia

  • Research Site

    Essen, 45147, Germany

  • Research Site

    Frankfurt, 60590, Germany

  • Research Site

    Hamburg, 20246, Germany

  • Research Site

    München, 81675, Germany

  • Research Site

    Solingen, 42653, Germany

  • Research Site

    Genova, 16132, Italy

  • Research Site

    Milan, 20141, Italy

  • Research Site

    Monza, 20052, Italy

  • Research Site

    Torino, 10126, Italy

  • Research Site

    Chūōku, 104-0045, Japan

  • Research Site

    Fukuoka, 811-1395, Japan

  • Research Site

    Matsuyama, 791-0280, Japan

  • Research Site

    Morioka, 028-3695, Japan

  • Research Site

    Shinjuku-ku, 160-8582, Japan

  • Research Site

    Yamagata, 990-9585, Japan

  • Research Site

    Yonago-shi, 683-8504, Japan

  • Research Site

    Amsterdam, 1066 CX, Netherlands

  • Research Site

    Amsterdam, 1105 AZ, Netherlands

  • Research Site

    Nijmegen, 6525 GA, Netherlands

  • Research Site

    Rotterdam, 3015 GD, Netherlands

  • Research Site

    Panama City, 2723, Panama

  • Research Site

    Lima, LIMA 27, Peru

  • Research Site

    Lima, LIMA 41, Peru

  • Research Site

    Madrid, 08035, Spain

  • Research Site

    Valencia, 46010, Spain

  • Research Site

    Birmingham, B18 7QH, United Kingdom

  • Research Site

    Coventry, CV2 2DX, United Kingdom

  • Research Site

    Edinburgh, EH4 2XR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.